Zdrowie i gospodarka · 07/10/2020

FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for FY 2021

The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2021, based on the average cost of reviewing human drug applications in the previous year.